Cabaletta Bio (CABA) Accumulated Depreciation (2019 - 2025)
Cabaletta Bio (CABA) posted quarterly Accumulated Depreciation of $7.2 million for Q4 2025, up 29.89% year-over-year from $5.5 million in Q4 2024, and up 29.89% quarter-over-quarter from $5.5 million in Q4 2024.
Cabaletta Bio (CABA) Accumulated Depreciation (2019 - 2025) Analysis & Trends
Cabaletta Bio's Accumulated Depreciation history runs 7 years deep, the most recent figure standing at $7.2 million for Q4 2025.
- In Q4 2025, Accumulated Depreciation rose 29.89% year-over-year to $7.2 million; the TTM figure through Dec 2025 stood at $7.2 million (up 29.89% YoY), while the FY2025 annual figure was $7.2 million, up 29.89% from the prior year.
- Accumulated Depreciation for Q4 2025 stood at $7.2 million, up from $5.5 million in the prior quarter.
- The five-year high for Accumulated Depreciation was $7.2 million in Q4 2025, with the low at $1.2 million in Q4 2021.
- The 5-year median for Accumulated Depreciation is $3.8 million (2023), against an average of $4.0 million.
- The sharpest annual moves came in 2021 and 2025: Accumulated Depreciation jumped 160.04% in 2021, then increased 29.89% in 2025.
- Cabaletta Bio's Accumulated Depreciation stood at $1.2 million in 2021, then jumped by 98.91% to $2.4 million in 2022, then surged by 60.19% to $3.8 million in 2023, then surged by 45.09% to $5.5 million in 2024, then increased by 29.89% to $7.2 million in 2025.
- Business Quant data shows CABA's Accumulated Depreciation at $7.2 million in Q4 2025, $5.5 million in Q4 2024, and $3.8 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.15 Mn |
| Dec 31, 2024 | 5.51 Mn |
| Dec 31, 2023 | 3.80 Mn |
| Dec 31, 2022 | 2.37 Mn |
| Dec 31, 2021 | 1.19 Mn |
| Dec 31, 2020 | 458,000.00 |
| Dec 31, 2019 | 104,000.00 |